Visceral leishmaniasis associated with Ixekizumab therapy
This paper reports the first documented case in the Mediterranean region of visceral leishmaniasis complicated by hemophagocytic lymphohistiocytosis in a patient treated with the IL-17 inhibitor ixekizumab, which was successfully managed with liposomal amphotericin B before the patient was switched to guselkumab.